192 related articles for article (PubMed ID: 19331595)
21. A controlled multicenter pediatric study in the treatment of acute respiratory tract diseases with the aid of a new specific compound, erdosteine (IPSE, Italian Pediatric Study Erdosteine).
Titti G; Lizzio A; Termini C; Negri P; Fazzio S; Mancini C
Int J Clin Pharmacol Ther; 2000 Aug; 38(8):402-7. PubMed ID: 10984014
[TBL] [Abstract][Full Text] [Related]
22. Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease.
Poole P; Chong J; Cates CJ
Cochrane Database Syst Rev; 2015 Jul; (7):CD001287. PubMed ID: 26222376
[TBL] [Abstract][Full Text] [Related]
23. Use of thiols and implications for the use of inhaled corticosteroids in the presence of oxidative stress in COPD.
Cazzola M; Page CP; Wedzicha JA; Celli BR; Anzueto A; Matera MG
Respir Res; 2023 Jul; 24(1):194. PubMed ID: 37517999
[TBL] [Abstract][Full Text] [Related]
24. Activity of erdosteine on mucociliary transport in patients affected by chronic bronchitis.
Olivieri D; Del Donno M; Casalini A; D'Ippolito R; Fregnan GB
Respiration; 1991; 58(2):91-4. PubMed ID: 1862257
[TBL] [Abstract][Full Text] [Related]
25. Effects of erdosteine on sputum biochemical and rheologic properties: pharmacokinetics in chronic obstructive lung disease.
Marchioni CF; Moretti M; Muratori M; Casadei MC; Guerzoni P; Scuri R; Fregnan GB
Lung; 1990; 168(5):285-93. PubMed ID: 2126836
[TBL] [Abstract][Full Text] [Related]
26. Impact of Mucolytic Agents on COPD Exacerbations: A Pair-wise and Network Meta-analysis.
Cazzola M; Rogliani P; Calzetta L; Hanania NA; Matera MG
COPD; 2017 Oct; 14(5):552-563. PubMed ID: 28753070
[TBL] [Abstract][Full Text] [Related]
27. Erdosteine affects eicosanoid production in COPD.
Dal Negro RW; Visconti M; Tognella S; Micheletto C
Int J Clin Pharmacol Ther; 2011 Jan; 49(1):41-5. PubMed ID: 21176724
[TBL] [Abstract][Full Text] [Related]
28. The Effect of Maintenance Treatment with Erdosteine on Exacerbation Treatment and Health Status in Patients with COPD: A Post-Hoc Analysis of the RESTORE Dataset.
Calverley PMA; Papi A; Page C; Rogliani P; Dal Negro RW; Cazzola M; Cicero AF; Wedzicha JA
Int J Chron Obstruct Pulmon Dis; 2022; 17():1909-1920. PubMed ID: 36034589
[TBL] [Abstract][Full Text] [Related]
29. Protective effects of erdosteine against doxorubicin-induced cardiomyopathy in rats.
Fadillioğlu E; Erdoğan H; Söğüt S; Kuku I
J Appl Toxicol; 2003; 23(1):71-4. PubMed ID: 12518339
[TBL] [Abstract][Full Text] [Related]
30. An overview of erdosteine antioxidant activity in experimental research.
Moretti M; Marchioni CF
Pharmacol Res; 2007 Apr; 55(4):249-54. PubMed ID: 17267240
[TBL] [Abstract][Full Text] [Related]
31. Clinical effects of erdosteine in the treatment of acute respiratory tract diseases in children.
Balli F; Bergamini B; Calistru P; Ciofu EP; Domenici R; Doros G; Dragomir D; Gherghina I; Iordachescu F; Murgoci G; Orasanu D; Plesca D; Vaccaro A; Assereto R
Int J Clin Pharmacol Ther; 2007 Jan; 45(1):16-22. PubMed ID: 17256446
[TBL] [Abstract][Full Text] [Related]
32. Protective role of erdosteine pretreatment on oleic acid-induced acute lung injury.
Erdem A; Gedikli E; Yersal N; Karaismailoglu S; Muftuoglu S; Fadillioglu E; Tuncer M
J Surg Res; 2017 Jun; 213():234-242. PubMed ID: 28601320
[TBL] [Abstract][Full Text] [Related]
33. Erdosteine enhances airway response to salbutamol in patients with mild-to-moderate COPD.
Dal Negro R; Visconti M; Trevisan F; Bertacco S; Micheletto C; Tognella S
Ther Adv Respir Dis; 2008 Oct; 2(5):271-7. PubMed ID: 19124377
[TBL] [Abstract][Full Text] [Related]
34. Antioxidants and mucolytics in COPD management: when (if ever) and in whom?
Hillas G; Nikolakopoulou S; Hussain S; Vassilakopoulos T
Curr Drug Targets; 2013 Feb; 14(2):225-34. PubMed ID: 23256719
[TBL] [Abstract][Full Text] [Related]
35. Effectiveness of erdosteine in elderly patients with bronchiectasis and hypersecretion: a 15-day, prospective, parallel, open-label, pilot study.
Crisafulli E; Coletti O; Costi S; Zanasi E; Lorenzi C; Lucic S; Fabbri LM; Bertini M; Clini EM
Clin Ther; 2007 Sep; 29(9):2001-9. PubMed ID: 18035199
[TBL] [Abstract][Full Text] [Related]
36. Oxidative stress and respiratory system: pharmacological and clinical reappraisal of N-acetylcysteine.
Santus P; Corsico A; Solidoro P; Braido F; Di Marco F; Scichilone N
COPD; 2014 Dec; 11(6):705-17. PubMed ID: 24787454
[TBL] [Abstract][Full Text] [Related]
37. Pemphigus herpetiformis-type drug reaction caused by erdosteine containing mucolytic in a child.
Akoglu G; Yavuz SO
Cutan Ocul Toxicol; 2017 Sep; 36(3):302-304. PubMed ID: 27881029
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of erdosteine in the treatment of chronic rhinosinusitis with nasal polyposis - a pilot study.
Hoza J; Salzman R; Starek I; Schalek P; Kellnerova R
Rhinology; 2013 Dec; 51(4):323-7. PubMed ID: 24260764
[TBL] [Abstract][Full Text] [Related]
39. Effect of CArbocisteine in Prevention of exaceRbation of chronic obstructive pulmonary disease (CAPRI study): An observational study.
Esposito A; Valentino MR; Bruzzese D; Bocchino M; Ponticiello A; Stanziola A; Sanduzzi A
Pulm Pharmacol Ther; 2016 Apr; 37():85-8. PubMed ID: 26970503
[TBL] [Abstract][Full Text] [Related]
40. Oxidation pathway and exacerbations in COPD: the role of NAC.
Matera MG; Calzetta L; Cazzola M
Expert Rev Respir Med; 2016; 10(1):89-97. PubMed ID: 26567752
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
